A Phase 1 Trial of Zelebrudomide (NX-2127), a First-in-Class BTK Dual-Targeted Protein Degrader, in Patients with Relapsed/Refractory B-cell Malignancies By webmaster / September 5, 2025
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase Degrader, Shows High Clinical Activity and Tolerable Safety in an Ongoing Phase 1a/b Study in Patients with Waldenström Macroglobulinemia By webmaster / September 5, 2025
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed/Refractory CLL: Updated Findings From an Ongoing Phase 1a Study By webmaster / September 5, 2025
Machine Learning Frameworks for Predictive PK/PD Modeling of Degraders from Fragmented Multi-Source Data By webmaster / July 22, 2025
Rewriting Established Drug Design Rules with a CNS-Penetrant Catalytic Bruton’s Tyrosine Kinase (BTK) Degrader By webmaster / July 22, 2025
From Incremental to Exponential: Integrating AI and DEL to Enable Discovery Across the Proteome By webmaster / July 22, 2025
Leveraging Degrader Antibody Conjugates and Novel Ligases to Achieve Superior Delivery, Efficacy and Selectivity By webmaster / July 22, 2025
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase Degrader, Shows High Clinical Activity and Tolerable Safety in an Ongoing Phase 1a/b Study in Patients with Waldenström Macroglobulinemia By webmaster / July 16, 2025
NRX-0305: A Pan-Mutant BRAF Degrader with Broad Preclinical Efficacy, Brain Penetrance, and Synergistic Potential with MEK Inhibition Across Class 1/2/3 BRAF-mutant Cancers By webmaster / April 25, 2025
Bexobrutideg (NX-5948) is a CNS-Penetrant Catalytic Bruton’s Tyrosine Kinase (BTK) Degrader that Breaks Established Design Rules for CNS Drugs By webmaster / April 25, 2025
